Ascendis Pharma (ASND) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $3.23
- EPS estimate
- $1.74
- EPS surprise
- +85.97%
- Revenue surprise
- +2.54%
- Revenue
- $387.5M
- Revenue estimate
- $377.9M
- Reported
- Aug 13, 2026
Ascendis Pharma reported Q2 2026 results on August 13, 2026. Earnings per share were $3.23, beating the $1.74 estimate by 85.97%. Revenue of $387.5 million topped the $377.9 million consensus by 2.54%. In Q2 2025, Ascendis posted a loss of $0.97 per share on $186.2 million of revenue, so revenue roughly doubled year over year.
The table shows a long run of losses that ended this year. Ascendis lost money in all 18 quarters from Q3 2021 through Q4 2025. Annual losses per share narrowed from $10.98 in 2022 to $9.05 in 2023, $7.11 in 2024 and $4.50 in 2025. Revenue rose from about $54 million in 2022 to about $837 million in 2025. Q1 2026 stands apart, with EPS of $11.26 against a $0.21 estimate, far above any other quarter here. The first half of 2026 totals $14.49 per share. Ascendis beat the EPS estimate in 10 of the last 20 quarters.
Ascendis reported Q3 between November 2 and November 14 in each of the past five years. That points to early or mid-November 2026 for the next report. It will show whether the company stays profitable.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 13, 2026 | $1.74 | $3.23 | +85.97% | $387.5M | SEC |
| Q1 2026 | May 7, 2026 | $0.21 | $11.26 | +5241.35% | $284.9M | SEC |
| Q4 2025 | Feb 11, 2026 | −$0.22 | −$0.65 | −187.62% | $290.7M | SEC |
| Q3 2025 | Nov 12, 2025 | −$0.29 | −$1.17 | −309.56% | $250.7M | SEC |
| Q2 2025 | Aug 7, 2025 | −$1.51 | −$0.97 | +36.23% | $186.2M | SEC |
| Q1 2025 | May 1, 2025 | −$1.59 | −$1.71 | −7.68% | $109.2M | SEC |
| Q4 2024 | Feb 12, 2025 | −$1.02 | −$0.66 | +35.00% | $180.0M | SEC |
| Q3 2024 | Nov 14, 2024 | −$1.74 | −$1.92 | −9.92% | $64.4M | SEC |
| Q2 2024 | Sep 3, 2024 | −$1.56 | −$2.05 | −30.96% | $38.6M | SEC |
| Q1 2024 | May 2, 2024 | −$1.59 | −$2.48 | −55.73% | $103.5M | SEC |
| Q4 2023 | Feb 7, 2024 | −$2.00 | −$1.70 | +15.13% | $152.0M | SEC |
| Q3 2023 | Nov 7, 2023 | −$2.51 | −$2.84 | −13.37% | $47.4M | SEC |
| Q2 2023 | Sep 5, 2023 | −$2.75 | −$2.36 | +14.38% | $51.7M | SEC |
| Q1 2023 | Apr 27, 2023 | −$2.88 | −$2.15 | +25.50% | $36.4M | SEC |
| Q4 2022 | Feb 16, 2023 | −$2.84 | −$3.96 | −39.64% | $24.1M | SEC |
| Q3 2022 | Nov 2, 2022 | −$2.49 | −$3.04 | −22.10% | $15.4M | — |
| Q2 2022 | Aug 10, 2022 | −$2.27 | −$1.53 | +32.52% | $6.5M | — |
| Q1 2022 | May 11, 2022 | −$2.28 | −$2.45 | −7.39% | $7.6M | — |
| Q4 2021 | Mar 2, 2022 | −$2.62 | −$2.11 | +19.24% | $5.6M | — |
| Q3 2021 | Nov 10, 2021 | −$2.67 | −$1.70 | +36.26% | $1.3M | — |
Quarterly revenue
Frequently asked questions
When did Ascendis Pharma (ASND) last report earnings?
Ascendis Pharma last reported on Aug 13, 2026, covering fiscal Q2 2026.
Did ASND beat earnings estimates?
Yes. Ascendis Pharma reported EPS of $3.23 for Q2 2026 against a $1.74 estimate — a 85.97% beat.
How much revenue did ASND report last quarter?
Ascendis Pharma reported $387.5M in revenue for Q2 2026, against a consensus estimate of $377.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.